These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 33747756)

  • 1. Innate and adaptive immune responses toward nanomedicines.
    Viana IMO; Roussel S; Defrêne J; Lima EM; Barabé F; Bertrand N
    Acta Pharm Sin B; 2021 Apr; 11(4):852-870. PubMed ID: 33747756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines.
    Thi TTH; Suys EJA; Lee JS; Nguyen DH; Park KD; Truong NP
    Vaccines (Basel); 2021 Apr; 9(4):. PubMed ID: 33918072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
    van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanosize drug delivery system.
    Mukherjee B
    Curr Pharm Biotechnol; 2013; 14(15):1221. PubMed ID: 25106648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The application of plant-exosome-like nanovesicles as improved drug delivery systems for cancer vaccines.
    Hillman T
    Discov Oncol; 2024 Apr; 15(1):136. PubMed ID: 38683256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomedicines for the Delivery of Biologics.
    Wahlich J; Desai A; Greco F; Hill K; Jones AT; Mrsny RJ; Pasut G; Perrie Y; Seib FP; Seymour LW; Uchegbu IF
    Pharmaceutics; 2019 May; 11(5):. PubMed ID: 31058802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harnessing Liposome Interactions With the Immune System for the Next Breakthrough in Cancer Drug Delivery.
    La-Beck NM; Liu X; Wood LM
    Front Pharmacol; 2019; 10():220. PubMed ID: 30914953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the Role of Anti-PEG Antibodies in the Complement Activation by Doxil in Vitro.
    Neun BW; Barenholz Y; Szebeni J; Dobrovolskaia MA
    Molecules; 2018 Jul; 23(7):. PubMed ID: 30002298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention.
    Szebeni J; Muggia F; Gabizon A; Barenholz Y
    Adv Drug Deliv Rev; 2011 Sep; 63(12):1020-30. PubMed ID: 21787819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles.
    Singh AP; Biswas A; Shukla A; Maiti P
    Signal Transduct Target Ther; 2019; 4():33. PubMed ID: 31637012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Micro and nanotechnologies: The little formulations that could.
    Stiepel RT; Duggan E; Batty CJ; Ainslie KM
    Bioeng Transl Med; 2023 Mar; 8(2):e10421. PubMed ID: 36925714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleic Acid Sensing Machinery: Targeting Innate Immune System for Cancer Therapy.
    Iurescia S; Fioretti D; Rinaldi M
    Recent Pat Anticancer Drug Discov; 2018; 13(1):2-17. PubMed ID: 29086701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines.
    Balasubramanian V; Liu Z; Hirvonen J; Santos HA
    Adv Healthc Mater; 2018 Jan; 7(1):. PubMed ID: 28570787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
    Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
    EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frontrunners in the race to develop a SARS-CoV-2 vaccine.
    Russell RL; Pelka P; Mark BL
    Can J Microbiol; 2021 Mar; 67(3):189-212. PubMed ID: 33264067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioinspired and Biomimetic Nanomedicines.
    Chen Z; Wang Z; Gu Z
    Acc Chem Res; 2019 May; 52(5):1255-1264. PubMed ID: 30977635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
    Frederiksen LSF; Zhang Y; Foged C; Thakur A
    Front Immunol; 2020; 11():1817. PubMed ID: 32793245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives.
    Gómez-Aguado I; Rodríguez-Castejón J; Vicente-Pascual M; Rodríguez-Gascón A; Solinís MÁ; Del Pozo-Rodríguez A
    Nanomaterials (Basel); 2020 Feb; 10(2):. PubMed ID: 32093140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19).
    Bennet BM; Wolf J; Laureano R; Sellers RS
    Toxicol Pathol; 2020 Oct; 48(7):800-809. PubMed ID: 32926660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.